Fierce Biotech April 30, 2024
Harmony Biosciences is adding a suite of epilepsy assets to its pipeline, buying Epygenix for $35 million upfront with more than $600 million in biobucks on the table.
The relatively small M&A deal announced Tuesday has large potential, with the purchase adding a third late-stage candidate to Harmony’s pipeline. Front and center is EPX-100, currently in a phase 3 study to treat Dravet syndrome in both adults and children. Epygenix is about to launch a second phase 3 study in children with Lennox-Gastaut syndrome, a rare epilepsy condition.
“The acquisition of Epygenix gives us three distinct CNS franchises in late-stage development, each with a potential US peak sales opportunity of $1B – $2B,” said Harmony President and CEO Jeffrey...
Today's Sponsors
Today's Sponsor